Nitric oxide and anti-protozoan chemotherapy;L'ossido nitrico nella terapia anti-protozoaria

Parassitologia

Volumn 46, Issue 1-2, 2004, Pages 101-103

  Gradoni, L ^a   Ascenzi, P ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; CYSTEINE PROTEINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE DONOR; NOS2 PROTEIN, MOUSE; NOS2A PROTEIN, HUMAN;

AMASTIGOTE; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; BRAIN MALARIA; CHEMICAL MODIFICATION; CHEMOTHERAPY; CONFERENCE PAPER; CREAM; CYTOTOXICITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; ENTAMOEBA HISTOLYTICA; ENZYME ACTIVITY; ENZYME INHIBITION; EPIMASTIGOTE; HEART DISEASE; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; LIFE CYCLE; LIVER CELL; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NAEGLERIA FOWLERI; NITROSYLATION; NONHUMAN; PARASITE SURVIVAL; PATHOGENESIS; PLASMODIUM; PLASMODIUM FALCIPARUM; PROMASTIGOTE; PROMOTER REGION; PROTEIN EXPRESSION; PROTOZOAL INFECTION; SKIN LEISHMANIASIS; TARGET CELL; TRICHOMONAS VAGINALIS; TRYPANOSOMA CRUZI; ANIMAL; CHEMISTRY; CHILD; CLINICAL TRIAL; DOG; DRUG SCREENING; ENZYMOLOGY; INTESTINE INFECTION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALIA; ENTAMOEBA; ENTAMOEBA HISTOLYTICA; GIARDIA; GIARDIA INTESTINALIS; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; MAMMALIA; MURINAE; NAEGLERIA; NAEGLERIA FOWLERI; PLASMODIUM FALCIPARUM; PROTOZOA; TRICHOMONAS VAGINALIS; TRYPANOSOMA; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; INTESTINAL DISEASES, PARASITIC; MACROPHAGES; MICE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROTOZOAN INFECTIONS;

EID: 4844230616     PISSN: 00482951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, Arnelle DR, Mollis D, McDonald MI, Granger DL (1996). Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 184: 557-567.
2. Ascenzi P, Salvati L, Bolognesi M, Colasanti M, Polticelli F, Venturini G (2001). Inhibition of cysteine protease activity by NO-donors. Curr Protein Pept Sci 2: 137-153.
3. Bogdan C, Gessner A, Solbach W, Rollinghoff M (1996). Invasion, control and persistence of Leishmania parasites. Curr Opin Immunol 8: 517-525.
4. Clark IA, Cowden WB (2003). The pathophysiology of falciparum malaria. Pharmacol Ther 99: 221-260.
5. Clark IA, Rockett KA (1996). Nitric oxide and parasitic disease. Adv Parasitol 37: 1-56.
6. Colasanti M, Suzuki H (2000). The dual personality of NO. Trends Pharmacol Sci 21: 249-252.
7. Colasanti M, Salvati L, Venturini G, Ascenzi P, Gradoni L (2001). Cysteine protease as a target for nitric oxide in parasitic organisms. Trends Parasitol 17: 575.
8. Colasanti M, Gradoni L, Mattu M, Persichini T, Salvati L, Venturini G, Ascenzi P (2002) Molecular bases for the anti-parasitic effect of NO (Review). Int J Mol Med 9: 131-134.
9. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N (2000). A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 94: 319-322.
10. Eckmann L, Laurent F, Langford TD, Hetsko ML, Smith JR, Kagnoff MF, Gillin FD (2000). Nitric oxide production by human intestinal epithelial cells and competition for arginine as potential determinants of host defense against the lumendwelling pathogen Giardia lamblia. J Immunol 164: 1478-1487.
11. Gobert AP, Semballa S, Daulouede S, Lesthelle S, Taxile M, Veyret B, Vincendeau P (1998). Murine macrophages use oxygen- and nitric oxide-dependent mechanisms to synthesize S-nitroso-albumin and to kill extracellular trypanosomes. Infect Immun 66: 4068-4072.
12. Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, Weinberg JB (2002). A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet 360: 1468-1475.
13. Huang H, Chan J, Wittner M, Jelicks LA, Morris SA, Factor SM, Weiss LM, Braunstein VL, Bacchi CJ, Yarlett N, Chandra M, Shirani J, Tanowitz HB (1999). Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice. J Mol Cell Cardiol 31:75-88.
14. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S (1990). Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794-4797.
15. Lòpez-Jaramillo P, Ruano C, Rivera J, Teran E, Salazar-Irigoyen R, Esplugues JV, Moncada S (1998). Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 351: 1176-1177.
16. Martins GA, Cardoso MA, Aliberti JC, Silva JS (1998). Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunol Lett 63: 113-120.
17. Mellouk S, Hoffman SL, Liu ZZ, de la Vega P, Billiar TR, Nussler AK (1994). Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect Immun 62: 4043-4046.
18. Park GC, Ryu JS, Min DY (1997). The role of nitric oxide as an effector of macrophage-mediated cytotoxicity against Trichomonas vaginalis. Korean J Parasitol 35: 189-195.
19. Salvati L, Mattu M, Colasanti M, Scalone A, Venturini G, Gradoni L, Ascenzi P (2001). NO donors inhibit Leishmania infantum cysteine proteinase activity. Biochim Biophys Acta 1545: 357-366.
20. Sannella A, Gradoni L, Persichini T, Ongini E, Venturini G, Colasanti M (2003). Intracellular release of nitric oxide by NCX 972, an NO-releasing metronidazole, enhances in vitro killing of Entamoeba histolytica. Antimicrob Agents Chemother 47: 2303-2306.
21. Seguin R, Mann BJ, Keller K, Chadee K (1997). The tumor necrosis factor alpha-stimulating region of galactose-inhibitable lectin of Entamoeba histolytica activates gamma interferon-primed macrophages for amebicidal activity mediated by nitric oxide. Infect Immun 65: 2522-2527.
22. Vespa GN, Cunha FQ, Silva JS (1994). Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 62: 5177-5182.
23. Zeina B, Banfield C, al-Assad S (1997). Topical glyceryl trinitrate: a possible treatment for cutaneous leishmaniasis. Clin Exp Dermatol 22: 244-245.